Back to results
US 2024/0393340 A1Published application
Prognosis and predictive biomarkers and biological applications thereof
AssigneesInstitut Gustave Roussy, Institut National de la Sante et de la Recherche Medicale, Universite Paris-Saclay
InventorsCAROLINE ROBERT, LISE BOUSSEMART, ISABELLE GIRAULT, STÉPHAN VAGNER
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of evaluating the sensitivity or resistance of a cancer cell to an antitumoral therapeutic treatment. It further relates to the treatment of a cancer with an inhibitor of the eiF4F complex used for the sensitisation of said cancer to an antitumoral therapeutic treatment.
Claims12
(canceled)
A method of treating cancer by selecting an appropriate treatment for a subject having a tumor, which method comprises:
- a step of determining the amount of the Cap-OFF and Cap-ON forms of the eiF4F complex in a biological sample of said subject, a high Cap-OFF/Cap-ON ratio in the biological sample being the indication that a treatment with an antitumoral agent will be efficient in the subject, a low Cap-OFF/Cap-ON ratio in the biological sample being the indication that a treatment with an antitumoral agent will not be efficient in the subject, and
- a step of administering to the subject (i) an antitumoral agent to the subject if the Cap-OFF/Cap-ON ratio is high or (ii) an antitumoral agent in combination with a compound increasing the Cap-OFF/Cap-ON ratio if the Cap-OFF/Cap-ON ratio is low.
Dependencies are inferred from the claim text.